Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers ABUS BRNS
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers ABUS BRNS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
New partnership aims to advance vaccine against MERS coronavirus
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers ABUS BRNS
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers BRNS
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
Tickers VACC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.